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Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak have been jointly awarded 
the 100th Nobel Prize in Medicine and Physiology for the discovery of “how chromosomes 
are protected by telomeres and the enzyme telomerase”. 
This discovery of basic research done in a primitive organism has been a breakthrough for 
the understanding of how cells successfully maintain cell division and turn into tumoral or 
senescent cells, with an important impact in human health and disease. Telomeres were fi 
rst described in 1930 by Hermann Müller (Nobel Prize 1945) and Barbara McClintock 
(Nobel Prize 1983) who observed in the fruit fl y (Drosophila melanogaster) and in maize 
(Zea mays) that natural chromosome ends had special properties and structures that 
played an essential function in their protection. These structures were called telomeres 
(from the Greek “telos” for end and “melos” for part) by Müller. Later, it was known that 
telomeres are terminal DNA-protein complexes that form capping structures in order to 
stabilize chromosome ends and prevent them from being recognized as DNA double-
strand breaks. 
 
Later on, in 1961, Leonard Hayflick developed the concept of cell immortality by 
discovering that human cells undergo a limited number of cell divisions, demonstrating 
the fi nite replicative capacity of normal human fi broblasts. The phenomenon was known 
as replicative senescence or the Hayfl ick limit. In the 1970s James Watson (Nobel Prize 
1962) reported that the properties of DNA replication prevent the cell from fully copying 
their linear chromosomes up to the ends. Replication takes place in the 5´-3´ direction and 
requires RNA primers. This poses a problem for the initiation of replication at the very end 
of the chromosomes. Watson called this the “end-replication problem”. Alexei Olovnikov 
found a link between this endreplication problem and cellular senescence (described by 
Hayfl ick). He postulated that the consecutive shortening of the DNA molecule in each 
round of replication might explain why normal cells can only divide a specifi c number 
of times and this can explain the Hayfl ick limit. 
 
In 1978 Elisabeth Blackburn, working in Joseph Gall‟s laboratory, found that telomeres 
from the ciliated protozoan Tetrahymena thermophila were formed by simple repeats of a 
6-base pair fragments with the sequence TTGGGG, which protected the chromosomes 
from degradation. Later on, Elizabeth Blackburn and Jack Szostak showed that the 
terminal repeated sequence of Tetrahymena could protect a linear plasmid from 
degradation in yeast. Therefore, these sequences conferred telomere function. In 1885 
Carol Greider and Elizabeth Blackburn discovered an enzyme that elongated telomeres 
and would compensate for the incomplete replication of telomere ends, allowing cells to 
divide without losing telomere repeats, and called this enzyme telomere terminal 
transferase. They purifi ed the enzyme and showed that it was a ribonucleoprotein 
complex, and both the RNA (hTR) and the protein (hTERT) were required for 
enzymatic activity [11], and gave this new type of DNA polymerase the name telomerase.  
 
 
Although this discovery was made in Tetrahymena, it was shown later that telomerase 
activity is the main mechanism by which telomeres are elongated in eukaryotes. J. 
Szostak, together with V. Lunbland, linked telomere shortening with the onset 
of cell senescence in yeast [12]. In parallel, researchers working on animal cells (C.B. 
Harley) proposed that the Hayfl ick limit was due to an excessive telomere shortening 
leading to cell senescence because of the lack of telomerase in somatic cells. In contrast, 
germline cells have telomerase activity and are able to maintain telomere length, thus 
bypassing senescence. In was in 1994 when a PCR-based TRAP assay for telomerase 
activity was developed, thus allowing detection of telomerase in a vast majority of human 
cancer cells, pointing to telomerase as a potential target for anticancer therapy. An animal 
model generated later on, a knockout mouse for the telomere RNA component (M. Blasco, 
1977), showed that telomerase was the main activity responsible for maintaining telomere 
length in mammals. In the absence of telomerase, mice suffered an accelerated rate of 
telomere shortening associated with ageing, age-associated pathologies and reduced 
longevity. 
 
In 1990, a telomerase-alternative mechanism of maintaining telomeres was described in 
yeast. A few years later, in 1994, the mechanism was described in mammals.  This 
mechanism was named „alternative lengthening of telomeres‟ (ALT). After all these pivotal 
discoveries, intensive research was developed in many laboratories and outstanding 
results were obtained in different aspects of telomere biology: telomerase composition 
assembly and regulation, composition of telomeric chromatin, drug development and 
telomere-independent functions of telomerase. 
 
Certainly all these fi ndings have represented important advances in the understanding of 
cancer and, more recently, other human diseases. Short telomeres are a barrier for cell 
division and, in agreement with this, most cancer cells activate telomerase during 
tumorigenesis to maintain a minimal telomere length (even if telomeres are not further 
elongated). Telomerase reactivation is known to be one of the landmarks of oncogenesis, 
as defi ned by R. Weinberg. Some tumour cells amplify both, telomerase genes, hTR and 
hTERT, in order to support tumour growth. Different strategies have been employed to 
inhibit telomerase in all kinds of tumour cells by targeting either hTR or hTERT or even the 
telomeres. However, although much effort has been concentrated in this task, few 
compounds are exploited clinically, mainly for reasons of low effectiveness or in vivo 
toxicity. Because hTERT is immunogenic, it represents also a suitable target for cancer 
immunotherapy. Initial clinical trials of multiple vaccine formulations containing peptide 
directed against hTERT epitopes suggest that an immunoprevention therapy for cancer 
might be possible. 
 
The implication of telomerase defi ciency in different syndromes has represented an 
important advance in their knowledge and a potential therapeutic approach for such 
diseases. Defi ciency in telomerase activity has been reported in haematopoietic 
syndromes such as dyskeratosis congenita, aplastic anaemia and, more recently, in 
different malignancies and myelodysplastic syndromes. Mutations in either hTR or hTERT, 
or other components of the telomerase complex, such as dyskerin, Nola2 and 
Nola3, have been found in these groups of patients. In other diseases, such as idiopathic 
pulmonary, liver and heart fi brosis, whose origin is chronic infl ammation in at least some 
patients, mutations in either hTR or hTERT were also found. 
 
Besides the genetic background, non-genetic environmental infl uences can impact on 
telomerase and telomere maintenance. This is the case for infl ammatory processes 
such as ulcerative colitis, and for obesity, cardiovascular disease, hypertension and 
chronic exposure to cigarette smoke. Determining the mechanisms by which telomerase 
activity is affected by external factors and by other metabolism and biochemical 
dysfunctions would help to better understand the role of telomerase in agerelated 
diseases. Recent reports from E. Blackburn‟s laboratory have shown that overproduction 
of glucocorticoids due to exposure to chronic psychological stress can compromise 
telomere maintenance and that exercise and diet control preserve telomere length and 
counteract chromosome instability that impact on tissue renewal and disease. 
 
The scientifi c discoveries of the 2009 Nobel Prize in Physiology and Medicine are 
excellent examples of the benefi ts that basic scientifi c research can provide to 
applied and clinical research. These fi ndings, although made in a simple organism such a 
Tetrahymena, have been shown to be pivotal in the understanding of diseases such as 
cancer, dyskeratosis congenita and other age-related diseases. Furthermore, they have 
provided opportunities for drug discovery of new therapies for both cancer and telomerase 
defi ciency syndromes. In the future it would help to understand how environment and 
lifestyle factors can contribute to telomere-based human ageing diseases. 
 
